PRESS RELEASE published on 01/07/2026 at 19:12, 9 months 25 days ago Inside Information / Other news releases ABIONYX Pharma releases half-yearly report on liquidity contract with TP ICAP (Europe) SA, detailing shares and cash balance for 2025 Liquidity Contract Shares TP ICAP Cash Balance ABIONYX Pharma
BRIEF published on 12/16/2025 at 21:23, 10 months 16 days ago ABIONYX Pharma Announces a Capital Increase Fundraising Capital Increase Biopharmaceutical ABIONYX Pharma Sepsis
BRIEF published on 12/16/2025 at 21:23, 10 months 16 days ago ABIONYX Pharma Announces €1.8 Million Capital Increase Capital Increase Subscription Rights Euronext Listing ABIONYX Pharma Financial Visibility
PRESS RELEASE published on 12/16/2025 at 21:18, 10 months 16 days ago Inside Information / Other news releases ABIONYX Pharma launches €1.8m capital increase with removal of preferential subscription rights, subscription price at 3.10 euros for new shares, extending financial visibility until 2026 Capital Increase Biopharma Preferential Subscription Rights ABIONYX Pharma Financial Visibility
BRIEF published on 12/05/2025 at 18:05, 10 months 27 days ago ABIONYX Reports Monthly Voting Rights and Share Data Euronext Paris Share Capital Voting Rights AMF Regulations ABIONYX Pharma
PRESS RELEASE published on 12/05/2025 at 18:00, 10 months 27 days ago Inside Information / Other news releases ABIONYX Pharma discloses monthly statement of total voting rights and shares as per French regulations. Company focused on innovative medicines in rare diseases Shares French Regulations Total Voting Rights ABIONYX Pharma Innovative Medicines
BRIEF published on 11/25/2025 at 18:38, 11 months 6 days ago ABIONYX Pharma Releases Q3 2025 Business Update Revenue Financial Update ABIONYX Pharma Q3 2025 Sepsis Research
PRESS RELEASE published on 11/25/2025 at 18:33, 11 months 6 days ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
BRIEF published on 11/12/2025 at 07:05, 11 months 20 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
BRIEF published on 10/21/2025 at 18:54, 1 year ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
Published on 10/30/2026 at 23:35, 2 days 9 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 9 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 14 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 17 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/02/2026 at 08:57, 8 minutes ago Original-Research: Rainbow Tours S.A. (von East Value Research GmbH ): BUY
Published on 11/02/2026 at 08:49, 16 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 11/02/2026 at 08:45, 19 minutes ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 11/02/2026 at 08:42, 22 minutes ago Turkiye Garanti Bankasi A.S.: Regarding the Sale of Non-Performing Loans Portfolio
Published on 10/30/2026 at 23:00, 2 days 10 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 15 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 21 hours ago Capital increase through exercise of subscription rights
